다형교아종 치료 시장 규모, 점유율과 동향 분석 리포트 : 치료별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment, By End-use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,833,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,318,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,288,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

다형교아종 치료 시장 요약

세계의 다형교아종치료 시장 규모는 2024년에 37억 2,000만 달러로 추정되며, 2033년까지 78억 7,000만 달러에 달할 것으로 예측됩니다.

2025-2033년의 CAGR은 8.68%로 전망되고 있습니다. 다형성 교모세포종(GBM)의 발병률 증가와 심각한 임상적 부담은 GBM 치료 산업에서 중요한 촉진요인입니다.

GBM 발생률은 진단 능력의 향상과 환자 수의 실질적 증가로 인해 전 세계에서 꾸준히 증가하고 있습니다. 특히 우려되는 것은 고령화에 따라 발병 위험이 높아짐에 따라 고령화 사회에서 GBM의 영향력이 커지고 있다는 점입니다. 전 세계 노인 인구가 계속 증가함에 따라 GBM 환자 수는 증가할 것으로 예상되며, 이는 의료 시스템에 더 많은 부담을 가중시키고 보다 효과적인 치료의 시급한 필요성을 강조하고 있습니다.

세계 의료기관의 데이터는 GBM의 임상적 부담 증가를 강조하고 있습니다. 예를 들어 2024년 12월 싱가포르의 파크웨이 암 센터는 연간 약 100건의 새로운 GBM 사례를 보고하여 싱가포르의 첨단 신경종양학 인프라에 대한 심각한 부담을 강조했습니다. GBM 환자는 보통 수술에 이어 방사선 치료와 항암화학요법을 병행하는 집중적이고 다학제적인 치료가 필요합니다. 그러나 몇 달 안에 재발이 빈번하게 발생하여 현재 치료법의 한계가 드러나고 있습니다. 이 센터의 보고서는 GBM 치료의 복잡성을 해결하기 위해 특히 유전체학과 면역치료의 통합을 통한 맞춤형 의료의 지속적인 발전의 중요성을 강조하고 있습니다.

또한 신경외과 분야의 첨단 기술의 통합은 GBM 환자의 치료 결과를 개선하고, 신흥 시장에서 치료 접근성을 더욱 확대하는 데 기여하고 있습니다. 예를 들어 수술 중 MRI(Io-MRI)는 종양 절제율을 향상시켜 수술 성공률을 크게 향상시킨다는 연구 결과가 있습니다. 2024년 'Journal of Neuro-Oncology'지에 게재된 연구에서는 Io-MRI 지원 수술로 완전 절제율이 33.6%에서 49.6%로 상승하고, 환자의 재발률이 감소하고 무진행 생존기간이 연장된 것을 확인했습니다.

이 치료법의 전 세계적인 보급 확대는 접근성 향상과 지원적인 상환 환경에 힘입은 바 큽니다. 여러 국가에서 의료제도가 TTF를 보험 적용 치료에 포함시켜 대상 환자들의 경제적 장벽을 없애고 있습니다. 노보큐어에 따르면 2024년 말 기준 전 세계 4,000명 이상의 환자가 옵튠 지오 TTF 시스템을 사용하고 있으며, 특히 미국, 독일, 프랑스, 일본에서 가장 많은 사용자 수를 기록하고 있다고 합니다. 이러한 환자 수 증가는 선진국과 신흥 헬스케어 시장 모두에서 TTF 요법에 대한 임상적 신뢰와 수용이 확대되고 있음을 보여줍니다. 또한 이 치료법의 성공은 GBM 이외의 새로운 적응증에 대한 기술 개선과 연구를 촉진하고 있습니다. 이러한 추세는 치료 환경을 재구성하고, TTF를 미래 GBM 치료 접근법의 중요한 요소로 자리매김하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 다형교아종치료 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 다형교아종치료 시장 : 치료별 비즈니스 분석

• 치료별 시장 점유율, 2024년 및 2033년
• 치료별 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 치료별, 2021-2033년
• 수술
• 방사선 치료
• 화학요법
• 표적치료(베바시주맙)

제5장 다형교아종치료 시장 : 최종 용도별 비즈니스 분석

• 최종 용도별 시장 점유율, 2024년 및 2033년
• 최종 용도별 부문 대시보드
• 시장 규모, 예측, 동향 분석, 최종 용도별, 2021-2033년
• 병원
• 클리닉/외래 센터
• 외래 수술 센터
• 기타

제6장 다형교아종치료 시장 : 국가별 추정·동향 분석

• 국가별 시장 점유율 분석, 2024년 및 2033년
• 국가별 시장 대시보드
• 시장 규모와 예측 동향 분석, 2021-2033년 :
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 참가자 개요
• 기업의 시장 현황 분석
• 기업 분류
• 전략 지도제작
• 기업 개요
  • Merck &Co., Inc.
  • Teva Pharmaceutical
  • Sun Pharma
  • Amneal Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • Amgen, Inc.
  • Pfizer Inc.
  • Arbor Pharmaceuticals(Azurity)
  • Karyopharm Therapeutics, Inc.

KSA

영문 목차

영문목차

Glioblastoma Multiforme Treatment Market Summary

The global glioblastoma multiforme treatment market size was estimated at USD 3.72 billion in 2024 and is projected to reach USD 7.87 billion by 2033, growing at a CAGR of 8.68% from 2025 to 2033. The rising prevalence of Glioblastoma Multiforme (GBM) and its significant clinical burden are critical drivers in the GBM treatment industry.

The incidence of GBM is steadily increasing worldwide, driven by both improved diagnostic capabilities and a genuine rise in the number of cases. Particularly concerning is the increasing impact of GBM on aging populations, as the risk of developing the disease escalates with age. With the global geriatric population continuing to grow, the number of GBM cases is projected to increase, placing additional strain on healthcare systems and underscoring the urgent need for more effective treatment options.

Data from healthcare institutions around the world highlight the growing clinical burden of GBM. For instance, in December 2024, Parkway Cancer Centre in Singapore reported approximately 100 new GBM cases annually, emphasizing the significant strain on the country's advanced neuro-oncology infrastructure. GBM patients typically require intensive, multidisciplinary care, involving surgery followed by concurrent radiotherapy and chemotherapy. However, relapses are common within months, highlighting the limitations of current treatment approaches. The center's report underscores the importance of continued advancements in personalized medicine, particularly through the integration of genomics and immunotherapies, to address the complexities of GBM treatment.

Moreover, the integration of advanced technologies in neurosurgery is improving GBM patient outcomes, further boosting treatment access in emerging markets. For example, studies have shown that intraoperative MRI (Io-MRI) significantly enhances surgery success by improving tumor resection rates. A 2024 study published in the Journal of Neuro-Oncology found that Io-MRI-assisted surgeries increased gross total resection rates from 33.6% to 49.6%, with patients experiencing lower recurrence rates and longer progression-free survival.

The therapy's growing global adoption is also being driven by improved access and supportive reimbursement environments. In several countries, health systems have incorporated TTF into covered treatment options, removing financial barriers for eligible patients. By the end of 2024, Novocure reported over 4,000 active patients on its Optune Gio TTF system globally, with significant user numbers in the U.S., Germany, France, and Japan. This growing patient base demonstrates the expanding clinical confidence and acceptance of TTF therapy across both developed and emerging healthcare markets. Additionally, the therapy's success is encouraging further technological refinements and research into new applications beyond GBM. Together, these trends are reshaping the therapeutic landscape, making TTF a key component of future GBM treatment approaches.

Global Glioblastoma Multiforme Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global glioblastoma multiforme treatment market report based on treatment, end-use, and region:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)
• Surgery
• Radiation Therapy
• Chemotherapy
  • Temozolomide
  • Lomustine
  • Carmustine Wafers
  • Other
• Targeted Therapy
• Tumor Treating Field (TTF) Therapy
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Clinics / Outpatient Centers
• Ambulatory Surgical Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Norway
  • Denmark
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2033
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
• 4.4. Surgery
  • 4.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
• 4.5. Radiation Therapy
  • 4.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
• 4.6. Chemotherapy
  • 4.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Temozolomide
    • 4.6.2.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Lomustine
    • 4.6.3.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Carmustine Wafers
    • 4.6.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6.5. Other
    • 4.6.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
• 4.7. Targeted Therapy (Bevacizumab)
  • 4.7.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Glioblastoma Multiforme Treatment Market: End-Use Business Analysis

• 5.1. End-Use Market Share, 2024 & 2033
• 5.2. End-Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
• 5.5. Clinics / Outpatient Centers
  • 5.5.1. Clinics / Outpatient Centers Market, 2021 - 2033 (USD Million)
• 5.6. Ambulatory Surgical Centers
  • 5.6.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Glioblastoma Multiforme Treatment Market: Countries Estimates & Trend Analysis

• 6.1. Country Market Share Analysis, 2024 & 2033
• 6.2. Country Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.3.1. U.S.
    • 6.3.1.1. Key Country Dynamics
    • 6.3.1.2. Target Disease Prevalence
    • 6.3.1.3. Regulatory Framework
    • 6.3.1.4. Reimbursement Framework
    • 6.3.1.5. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Target Disease Prevalence
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. Reimbursement Framework
    • 6.3.2.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Target Disease Prevalence
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Reimbursement Framework
    • 6.3.3.5. Mexico Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. UK Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. Germany Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. France Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Target Disease Prevalence
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Reimbursement Framework
    • 6.4.5.5. Italy Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Target Disease Prevalence
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Reimbursement Framework
    • 6.4.6.5. Spain Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Target Disease Prevalence
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Reimbursement Framework
    • 6.4.7.5. Denmark Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Target Disease Prevalence
    • 6.4.8.3. Regulatory Framework
    • 6.4.8.4. Reimbursement Framework
    • 6.4.8.5. Sweden Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key Country Dynamics
    • 6.4.9.2. Target Disease Prevalence
    • 6.4.9.3. Regulatory Framework
    • 6.4.9.4. Reimbursement Framework
    • 6.4.9.5. Norway Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. India Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Australia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. South Korea Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Thailand
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Thailand Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Middle East and Africa
  • 6.7.1. Middle East and Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. South Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. Saudi Arabia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Target Disease Prevalence
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Reimbursement Framework
    • 6.7.4.5. UAE Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Target Disease Prevalence
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Reimbursement Framework
    • 6.7.5.5. Kuwait Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Merck & Co., Inc.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Teva Pharmaceutical
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Sun Pharma
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Amneal Pharmaceuticals
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. F. Hoffmann-La Roche Ltd.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Amgen, Inc.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Pfizer Inc.
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Arbor Pharmaceuticals (Azurity)
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Karyopharm Therapeutics, Inc.
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives

관련자료